Clinical trials: Fatty Liver, Nonalcoholic
Transient Elastography, MASLD
Hepatic Elastography-Enhanced Lifestyle Modification in MASLD
The 2022 National Health Survey in Thailand revealed a substantial rise in obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
- Conditions
- Transient Elastography, MASLD, BMI, Metabolic Syndrome
- Trial name
- NCT06826807
- Testing
- Regular monitoring with transient elastography
- Where
- Thailand
- Volunteers
- 92 people
- Sponsor
- Mahidol University
Non-Alcoholic Fatty Liver Disease
Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease
The worldwide impact of obesity suggests an urgent need for solutions to decrease its burden on modern society. It has been generally understood that obesity is caused by a simple imbalance in the intake of energy in the form of…
- Trial name
- NCT04594954
- Testing
- Diet, FMT, Physical Activity
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Obesity, NAFLD
Effects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD
The aim of the study is to estimate the effectiveness of two different exercise programs combined with the Mediterranean diet versus diet alone on inflammatory status in subjects aged 18-65 years with obesity (BMI>30) and…
- Trial name
- Obesity_AF (NCT06186869)
- Testing
- Aerobic Exercise and diet intervention, Hiit and diet intervention, Diet
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Fatty Liver, Hepatic Steatosis
The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics
The purpose of this study is to determine whether probiotics, bacteria that may improve liver health, can effectively treat a chronic condition in diabetics that increases fat in the liver.
- Conditions
- Fatty Liver, Hepatic Steatosis, Diabetes Mellitus, Liver Diseases
- Trial name
- NCT00068094
- Testing
- Probiotic-containing powder
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Obesity, Diabetes Mellitus
Characterization of the Microbiome in Peritoneum, Jejunum, Rectum and Stool
Characterization of the human microbiome in the jejunum and comparison to the microbiome in the rectum and stool in order to see how the microbial communities change within the intestines.
- Conditions
- Obesity, Diabetes Mellitus, Fatty Liver, Nonalcoholic, Leaky Gut Syndrome
- Trial name
- METABIOM (NCT04067440)
- Testing
- Microbial Swab
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universität des Saarlandes
Non-alcoholic Steatohepatitis
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a…
- Trial name
- NCT06716905
- Testing
- ACT500 tablets
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Nonalcoholic Steatohepatitis (NASH)
Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.
- Trial name
- NCT02443116
- Testing
- NGM282
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 254 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT07854782
- Testing
- ALN-CIDEB
- Volunteers
- 1,500 people
- Sponsor
- Regeneron Pharmaceuticals
NAFLD
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD
- Trial name
- NCT03744182
- Testing
- HM15211
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Steatohepatitis
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
The main aim of this study is to evaluate the safety and tolerability of ontamalimab in participants with a liver disease called nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) with…
- Trial name
- NCT07052682
- Testing
- Ontamalimab
- Where
- 15 sites in United States
- Volunteers
- 11 people
- Sponsor
- Takeda
Non-Alcoholic Fatty Liver Disease
Lifestyle Guidance Methods in NAFLD
To determine the efficiency of lifestyle modification (due to a dietitian or digital application) compared to standard of care.
- Trial name
- INDIANA (NCT05792488)
- Testing
- Coach, App, Standard of care
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Ziekenhuis Oost-Limburg
NAFLD
Study of Losartan in the Treatment of NAFLD in Children
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease among children and is closely associated with obesity and the metabolic syndrome.
- Trial name
- NCT01913470
- Testing
- Losartan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Miriam Vos, MD
Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
The purpose of this study is to learn more about how the body stores fat in and around organs (for example in the liver) and why this affects some people's health more than others.
- Conditions
- Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Metabolically Abnormal Obesity, Metabolically Normal Obesity
- Trial name
- NCT01104220
- Testing
- Weight loss
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Nonalcoholic Fatty Liver Disease
Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease is one of the most common chronic liver diseases worldwide. Nonalcoholic steatohepatitis (NASH) is the active form of the disease which runs a progressive course and may result in liver cirrhosis…
- Trial name
- NCT01210989
- Testing
- Phyllanthus urinaria
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
HIV, HIV-Infections
The Visceral Adiposity Measurement and Observation Study
The Visceral Adiposity Measurement and Observation Study
- Conditions
- HIV, HIV-Infections, HIV-1-infection, HIV I Infection
- Trial name
- VAMOS (NCT05383456)
- Testing
- Diagnostic Test, HIV Anti-retroviral Background Therapy
- Where
- 8 sites in United States
- Volunteers
- 196 people
- Sponsor
- Theratechnologies
Obesity & Overweight, Diabetes Mellitus, Type 2
Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
This is a nationwide, multi-center, long-term follow-up study of overweight and obese adults in China. The study aims to recruit approximately 26,000 participants across 39 hospitals to better understand how body weight affects…
- Conditions
- Obesity & Overweight, Diabetes Mellitus, Type 2, Hypertension, Non-alcoholic Fatty Liver Disease (MASLD)
- Trial name
- NCT07884903
- Testing
- No intervention; observational assessment only
- Where
- China
- Volunteers
- 25,974 people
- Sponsor
- Shanxi Bethune Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
Study to Evaluate the Effectiveness of Legalon®
This is a multinational, multicentre, prospective, non-interventional study (NIS) in non-alcoholic fatty liver disease (NAFLD) patients with concomitant metabolic syndrome treated with Legalon® combined with diet and exercise.
- Trial name
- NCT05051527
- Testing
- Legalon® 140 mg
- Where
- Thailand
- Volunteers
- 362 people
- Sponsor
- Mylan Inc.
Non-Alcoholic Fatty Liver Disease
Aronia and Non-alcoholic Fatty Liver Disease
Adults newly diagnosed with NAFLD will be included in the study. At the beginning of the research, the socio-demographic characteristics and nutritional habits of the individuals will be questioned with a face-to-face…
- Trial name
- NCT06450769
- Testing
- Aronia juice, Mediterranean diet, Low-fat diet
- Volunteers
- 54 people
- Sponsor
- Istanbul Kent University
Diabetes Mellitus, Type 2
Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects
The objective of this early feasibility study is to evaluate the safety and performance of intravascular hepatic denervation using the Metavention Integrated Radio Frequency Denervation System (iRF System) to improve glycemic…
- Trial name
- DeLIVER (NCT04285554)
- Testing
- iRF System Hepatic Denervation
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Metavention
NAFLD Cirrhosis
Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
The role of Dapagliflozin in the improvement in CKD in both diabetic and non-diabetic patients has been evaluated in the past. SGLT2i have also been found to be beneficial in NAFLD patients in improving the liver function…
- Trial name
- NCT05849220
- Testing
- Dapagliflozin, Standard of Care
- Where
- India
- Volunteers
- 144 people
- Sponsor
- Institute of Liver and Biliary Sciences, India